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ABSTRACT
Occult residual disease in remnant tissues could be the cause of tumor 
relapse. To identify signal molecules and target cells that may be indicative of 
occult residual disease within a remnant microenvironment, proximal resection 
margin tissues of gastric cancers were used, as these correspond to the nearest 
remnant tissues after gastrectomy. Increased miR-146b-5p in the remnant 
microenvironment was determined to be a strong risk factor for tumor relapse 
and poor survival rate. NOVA1, a target gene of miR-146b-5p, was decreased 
in remnant tissues of patients with a poor prognosis. NOVA1 was enriched in 
stromal spindle cells such as fibroblasts within normal tissues. In non-neoplastic 
inflammation, such as gastritis, NOVA1 was highly enriched in T lymphocytes and 
stromal spindle cells, while expression of this protein was frequently decreased in 
those types of cells within gastric cancer tissues. Particularly, decreased NOVA1 
in T cells within the gastric cancer tissues was correlated with decreased FOXP3-
positive regulatory T cells and was associated with poor patient prognosis. In vitro 
analysis showed that the NOVA1 gene was inhibited by miR-146b-5p. In immune 
cells as well as stromal spindle cells, decreased NOVA1, possibly inhibited by miR-
146b-5p, is a candidate biomarker predicting poor prognosis of gastric cancer 
patients and is also a biomarker of occult residual disease in remnant tissues after 
gastric cancer removal.
INTRODUCTION
Tumor recurrence is a major cause of cancer death. 
Occult residual disease may be the source of locoregional 
or metastatic recurrence after initial treatment. [1, 2] 
Therefore, early detection and control of occult residual 
disease is a critically important issue. Previous studies 
designed to detect occult residual disease prior to relapse 
have focused on detecting occult tumor cells. In studies 
of head and neck cancer, lung cancer, and prostate cancer, 
occult tumor cells not detected by conventional histologic 
examination were found in resection margin tissues using 
molecular methods involving DNA and RNA markers. 
The molecular markers detected in the resection margin 
tissues were correlated with recurrence in these studies.
[3–6] Together with occult tumor cells, however, a tumor-
promoting microenvironment and associated molecules 
could also be present in the remnant tissues of cancer 
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patients, and these factors should also be considered when 
defining and controlling occult residual disease.
The microenvironment is an important contributor 
to the survival and growth of cancer cells. Tumor growth 
involves co-evolutionary processes among tumor cells, 
the extracellular matrix, the vasculatures, and immune 
cells.[7] The extracellular matrix, stromal spindle cells, 
vasculatures, and immune cells extend continuously 
from the original tumor field to the surrounding remnant 
tissues. Therefore, oncogenic changes that occur 
within the tumor microenvironment could extend into 
surrounding tissues and abnormally regulate resident cells 
in the remnant microenvironment. Although the remnant 
microenvironment may appear to be tumor cell-free 
in terms of conventional histology, ongoing molecular 
changes may result in clinically apparent tumor relapse. 
Therefore, investigation of occult residual disease should 
include consideration of the microenvironment and 
associated signaling molecules.
In gastric cancer surgery, the tumor mass and 
adjacent normal tissues are radically resected, and the 
remnant tissues are anastomosed (Figure 1).[8] Therefore, 
resection-margin status is important, as tumor presence 
in this area infers that there may be residual tumor cells 
in the remnant tissues. A tumor-positive resection margin 
has been shown to have a significant negative effect on 
the survival of gastric cancer patients.[9–12] However, 
even after curative (R0) resection, which is defined as 
complete tumor resection with all margins histologically 
negative[9], and adjuvant systemic chemotherapy, 
locoregional and distant relapse frequently occur in 
advanced gastric cancer patients, resulting in treatment 
failure and cancer death.[13] Occult residual disease 
within the remnant tissues may be the cause of such 
recurrences in that the cellular and structural components 
of the microenvironment extend from the original tumor 
field to the remnant tissues.
In this study, we investigated whether we could 
detect occult residual disease in remnant tissue that 
was histologically tumor-free at the time of surgical 
cancer resection. Furthermore, we examined the effects 
of such residual disease on patient outcomes, such as 
recurrence and cancer death. In particular, we focused 
on epigenetic dysregulation that involved microRNA 
in order to detect occult residual disease in remnant 
tissues. We characterized abnormally regulated cells 
and the associated molecular changes within the 
microenvironment; these factors are the potential 
components of occult residual disease, which is correlated 
with a poor clinical outcome.
To detect occult residual disease in remnant tissues, 
we selected proximal resection margin tissue sections of 
gastric cancers. When considering conventional surgical 
and pathologic examination protocols for gastric cancer, 
the proximal resection margin tissue is defined as being 
located between the original tumor field and the remnant 
tissues. The site of the proximal resection margin is the 
counter section of remnant tissues nearest to the original 
tumor (Figure 1).[8, 14, 15] The microenvironment of 
the proximal resection margin area could be the shortest 
pathway by which potential occult residual disease 
crosses into remnant tissues; we hypothesized that this 
area was therefore the remnant microenvironment where 
occult residual disease, if present, would be detectable 
(Figure 1).
RESULTS
Profiles of aberrantly expressed miRNAs
Candidate microRNAs showing aberrant expression 
in the remnant microenvironment were identified 
using positive (n = 4) and negative (n = 4) controls of 
proximal resection margin tissues. The positive control 
samples were of proximal resection margin tissues from 
R1 resection containing low numbers of tumor cells and 
were obtained from gastric cancer patients who died of 
cancer relapse; the negative control samples were of 
tumor cell-free (R0) proximal resection margin tissues 
and were obtained from gastric cancer patients with 
a favorable prognosis (Supplementary Table S1). In 
microarray analysis containing probes specific for 1205 
human and 144 human viral miRNAs, nine miRNA 
markers (hsa-miR-223-3p, -142-5p, -146b-5p, -150-5p, 
-363-5p, -532-5p, -502-3p, -1244, and -132-5p) were 
significantly increased and three (hsa-miR-933, -638, 
-3195) were significantly decreased in positive control 
samples compared to negative control samples. These 
12 miRNAs were considered to be candidate miRNA 
markers. Expression data are summarized in Table 1 and 
Supplementary Data Set 1.
miRNA markers correlated with poor oncologic 
outcomes
The 12 candidate miRNAs were analyzed in the 
set of proximal resection margin tissue samples (n 
= 140), which were determined to be histologically 
tumor-free (R0 resection) after curative radical 
surgery of gastric cancers. Changes in the expression 
of these candidate miRNAs were analyzed in terms 
of clinical and prognostic implications. Increased 
expressions of miR-146b-5p and miR-150-5p in the 
proximal resection margin tissues had significant 
clinicopathological implications and were correlated 
with poor oncologic outcomes. The overall correlations 
of the miRNA expression patterns of these two markers 
with clinicopathological factors and tumor relapse are 
summarized in Supplementary Table S2.
miR-146b-5p expression in the tested 
microenvironment was negatively correlated with 
distance from the edge of the original tumor mass (r = 
−0.26, P = 0.002; Figure 2A). For miR-150-5p, a similar 
tendency was noted, though without statistical significance 
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(r = −0.14, P = 0.099; Figure 2B). High expressions (fold 
change > two fold the median value of normal gastric 
tissues of cancer-free individuals) of miR-146b-5p and 
miR-150-5p were noted in 55.7% (78 of 140) and 39.3% 
(55 of 140) of tested cases, respectively. High expressions 
of miR-146b-5p and miR-150-5p were more frequently 
noted in higher pN-category tumors than in lower pN-
category tumors (P = 0.050 and 0.008, respectively; 
Supplementary Table S2). There was no difference in 
miR-146b-5p or miR-150-5p expression according to the 
method of gastrectomy (subtotal distal gastrectomy versus 
total gastrectomy; Supplementary Table S2).
During the follow-up period after surgery and 
adjuvant therapy, recurrence within the intraperitoneal 
Figure 1. The sample model for studying remnant microenvironments. Tumor cells, associated microenvironment cells, and 
signaling molecules could spread widely through the stromal matrix and vasculatures to the surrounding area (grey color). Part of the 
surrounding area (grey) influenced by the original tumor could remain even after removal of tumor and adjacent non-tumor tissues by 
subtotal gastrectomy A. or total gastrectomy B. Occult residual disease may be present in the remnant microenvironment (grey; A-C) 
after tumor removal. To prove occult residual disease in remnant tissues, the proximal resection margin section (tested area; red) was 
investigated; the proximal resection margin section was sampled from the resection line nearest from the original tumor mass in the case 
of subtotal gastrectomy (a) or total gastrectomy (b). Therefore, the proximal resection margin represents the section of remnant tissues 
nearest the original tumor mass. The microenvironment of the proximal resection margin area is located within the pathway where tumor-
permissive or tumor-promoting changes extend into the nearest remnant tissues (grey); these changes could be the main component of 
occult residual disease.
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area, which corresponds to the locoregional area 
adjacent to the remnant microenvironment, occurred 
more frequently in cases with high miR146b-5p 
expression than in those with non-high miR-146b-5p 
expression (18.5% vs. 5.7%; P = 0.038). Cases with 
high miR-150-5p expression were also found to have 
more frequent intraperitoneal recurrence than those with 
non-high miR-150-5p expression, with the difference 
being marginally significant (20.5% vs. 8.1%; P = 
0.052). High miR-146b-5p expression was more 
correlated with intraperitoneal recurrence and/or distant 
metastasis than non-high miR-146b-5p expression 
(26.2% vs. 9.4%; P = 0.020). For miR-150-5p, this 
tendency was noted with marginal significance (27.3% 
vs. 13.5%; P = 0.063). The results are summarized in 
Supplementary Table S2.
Based on the Kaplan-Meier survival analysis with a 
log-rank test for relapse-free survival, high miR-146b-5p 
expression was more correlated with a shorter interval to 
relapse (recurrence and/or metastasis) than non-high miR-
146b-5p expression (P = 0.025; Figure 2C). For miR-150-
5p, such a tendency was noted with marginal significance 
(P = 0.056; Figure 2D). Using the same method of analysis 
for overall survival (OS), high miR-146b-5p and miR-150-
5p expression were found to significantly correlate with 
inferior OS (P = 0.019 and 0.003, respectively; Figure 2E 
and 2F). Based on a multivariate analysis using the Cox 
proportional hazards model, miR-146b-5p high expression 
was found to be an independent risk factor for inferior OS 
(Supplementary Table S3). The distance (safety margin) to 
the proximal or distal resection margin had no significant 
effect on survival.
Potential target genes of miR-146b-5p
Considering that high miR-146b-5p expression in the 
histologically tumor-free microenvironment of proximal 
resection margin tissues was correlated with a poor 
oncologic outcome, we searched for potential target genes 
of miR-146b-5p by comparing proximal resection margin 
tissues from cases with high miR-146b-5p expression 
and poor oncologic outcomes (died of cancer relapse, 
n = 12) with those from cases with non-high miR-146b-5p 
expression and a favorable prognosis (n = 23). These cases 
were randomly selected among the set of 140 proximal 
resection margin samples after quality assessment of 
extracted mRNA. Using the microarray analysis containing 
probes specific for 27 predicted target genes of miR-146b-
5p, NOVA1 (neuro-oncological ventral antigen 1) mRNA 
expression was identified as a candidate target gene. The 
NOVA1 mRNA expression level was negatively correlated 
with the expression level of miR-146b-5p (r = −0.396, 
P = 0.018; Figure 3A) and significantly decreased in the 
group with high miR-146 expression and poor oncologic 
outcomes compared to the group with non-high miR-146b-
5p expression and favorable oncologic outcomes (P = 
0.034; Figure 3B). Overall expression data are summarized 
in Supplementary Table S4 and Supplementary Data Set 2.
Cellular localization of NOVA1 protein 
expression in non-tumor gastric tissues and 
gastric cancer tissues
In non-tumor gastric tissues (n = 45), strong 
NOVA1 protein expression was frequently observed 
Table 1. The miRNA markers showing significant difference between positive controls and negative controls
miRNA Chromosome 
locus
Log ratio Fold change Regulation P-value
hsa-miR-223-3p chrX 2.8 7.0 up 0.048
hsa-miR-142-5p chr17 2.6 6.2 up 0.023
hsa-miR-146b-5p chr10 2.3 5.0 up 0.007
hsa-miR-150-5p chr19 2.3 4.9 up 0.032
hsa-miR-362-5p chrX 1.0 2.0 up 0.003
hsa-miR-532-5p chrX 0.8 1.7 up 0.012
hsa-miR-502-3p chrX 0.7 1.7 up 0.038
hsa-miR-1244 chr2 0.7 1.6 up 0.048
hsa-miR-132-5p chr17 0.6 1.5 up 0.041
hsa-miR-933 chr2 −0.8 −1.7 down 0.033
hsa-miR-638 chr19 −0.7 −1.6 down 0.004
hsa-miR-3195 chr20 −0.7 −1.6 down 0.009
The log ratio (log2 ratio) and the fold change are calculated by comparing the mean expression of each miRNA marker in 
positive controls and negative controls.
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Figure 2. The clinical implications of miR-146b-5p and miR-150-5p. The expression level of miR-146b-5p in the proximal resection 
margin section was negatively correlated with distance from the original tumor. However, high miR-146b-5p expression, which was defined as 
when the fold change was more than two fold the median value of normal gastric tissues of cancer-free individuals (cut-off for high expression), 
was also frequently observed in distant areas. A. For miR-150-5p, a similar tendency was noted, although with marginal significance B. The 
correlation coefficient (r) with statistical significance (P value) between the miR expression level and the distance from the original tumor was 
determined using the Pearson correlation test (A and B). On survival analysis for recurrence-free survival, high miR-146b-5p expression was 
associated with a shorter interval to recurrence/metastasis C. For miR-150-5p, a similar tendency was noted, though with marginal significance 
D. Information on the relapse (intraperitoneal recurrence and distant metastasis) was not clear in some cases due to lack of clinical, radiological, 
and/or pathological information; therefore, recurrence-free survival was analyzed in 118 cases that had reliable information for relapse during 
the follow-up time. In survival analysis for overall survival (OS), high miR-146b-5p and -150-5p expression were significantly correlated with 
inferior OS E. and F. (respectively). Survival function curves and survival rates for recurrence-free survival (C and D) and overall survival (E 
and F) were determined using the Kaplan-Meier method, and differences in survival rates were compared using the log-rank test.
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in epithelial cells of gastric glands, immune cells of 
lymphoid structures, and stromal spindle cells, such as 
fibroblasts, reticular support cells, and endothelial cells, of 
the extracellular matrix spanning the gastric wall (Figure 
4A–4C). In advanced gastric cancer tissues (n = 250), 
weak NOVA1 protein expression was frequently noted in 
tumor cells (epithelial cells) as well as in stromal spindle 
cells and immune cells within the original tumor mass-
embedded microenvironment (Figures 4D–4G). Strong 
NOVA1 expression in the gastric cancer microenvironment 
was noted occasionally (Figures 4H and 4I).
When comparing the NOVA1 expression patterns in 
stromal spindle cells, immune cells, and epithelial cells 
(gastric gland cells or cancer cells) between non-tumor 
gastric tissues and gastric cancer tissues, the proportions 
of weak, moderate, and strong NOVA1 expression 
were different. In spindle cells (reticular support cells, 
fibroblasts, endothelial cells) of the gastric cancer field, 
weak NOVA1 expression was more frequent, and strong 
NOVA1 expression was relatively less frequent than cells 
of non-tumor gastric tissue (P < 0.001; Figures 4J). For 
immune cells and cancer cells (epithelial cells), similar 
expression patterns of NOVA1 were observed between 
gastric cancer tissues and non-tumor gastric tissues (both 
P < 0.001; Figure 4K and 4L). The expression patterns of 
NOVA1 among stromal spindle cells, immune cells, and 
tumor cells were closely correlated to each other (all P < 
0.001; Figure 4M–4O).
In this set of advanced gastric cancer tissues, 
attenuated or suppressed NOVA1 protein expressions in 
stromal spindle cells, immune cells, and tumor cells were 
associated with inferior overall survival compared to cases 
with strong NOVA1 protein expression (P = 0.011, 0.007, 
and 0.014, respectively; Figure 5A–5C).
Cellular localization of NOVA1 
protein expression in the normal tissue 
microenvironment
Stromal spindle cells as well as immune cells 
are the major components of inflammation within 
the tissue microenvironment.[16] Inflammation or 
a tertiary lymphoid structure corresponds to ectopic 
lymphoid accumulations in response to stimuli, and the 
structure is made by various immune cells and matrix 
components.[16–20] The non-tumor gastric tissues we 
examined frequently had inflammation in the form of 
chronic gastritis or Helicobacter gastritis. Therefore, the 
expression pattern of NOVA1 that we observed in non-
tumor gastritis may have reflected active inflammatory 
processes rather than the normal non-activated (inflamed) 
tissue condition. To identify NOVA1 protein expression 
in normal physiologic lymphoid structures (or secondary 
lymphoid structures), non-inflamed palatine tonsils were 
analyzed, as tonsils normally contain well-developed 
lymphoid structures.[19, 20]
In normal palatine tonsils (n = 10), cells with strong 
NOVA1 protein expression were distributed throughout 
the microenvironment (the cortical zone of lymphoid 
follicles, the paracortical zone, and the extracellular 
matrix). NOVA1-expressing cells were regularly scattered 
as single isolated cells (Figures 6A–6L). Scattered 
Figure 3. NOVA1 (neuro-oncological ventral antigen 1) as the predicted target genes of miR-146b-5p. Among the predicted 
target genes of miR-146b-5p, NOVA1 (neuro-oncological ventral antigen 1) expression was negatively correlated with the expression level 
of miR-146b-5p. The correlation coefficient (r) with statistical significance (P value) between the NOVA1 mRNA expression level and 
the miR-146b-5p expression level was determined using the Pearson correlation test A. NOVA1 mRNA levels significantly decreased in 
proximal resection margin tissues characterized by high miR-146 expression and poor oncologic outcomes compared to those with non-
high miR-146b-5p expression and favorable oncologic outcomes. The statistical significance was determined by the Mann-Whitney U test 
B. Statistically significant differences are indicated by *, which signifies P < 0.05.
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NOVA1-expressing cells had cytological features of 
fibroblasts or reticular support cells, with large-sized and 
ovoid-to-spindle-shaped nuclei. Stromal reticular support 
cells and fibroblasts in the extracellular matrix consistently 
showed strong NOVA1 expression (Figure 6A). In areas 
where alpha smooth muscle actin-positive stromal support 
cells, myofibroblasts, or fibroblasts were proliferating, 
NOVA1 was strongly enriched (Figures 6B–6D). S100 or 
c-Kit-positive spindle cells were also occasionally noted 
in the NOVA1-enriched area (Supplementary Figure S1). 
Mature endothelial cells expressed NOVA1 with variable 
intensity (from negative to moderate staining; Figures 
6A and 6J). In the cortical and paracortical areas where 
immune B cells, T cells, and macrophages/dendritic cells 
were resident, almost all B cells, follicular dendritic 
cells, and macrophages/dendritic cells were negative 
Figure 4. NOVA1 protein expression in non-tumor gastric tissues and gastric cancer tissues. Strong NOVA1 expression 
was frequently observed throughout the microenvironment of non-tumor gastric tissues A–C. Epithelial cells of glands (thin arrow; A), 
stromal spindle cells such as fibroblasts or support cells (thin arrows; B), endothelial cells (dotted arrow; B) of the extracellular matrix, 
and immune cells of lymphoid structures (thick arrow; C) showed strong NOVA1 expression. Immune cells scattered within the lamina 
propria (thick arrow; A) and extracellular matrix (thick arrow; B) also showed strong NOVA1 expression. Immune cells expressing NOVA1 
morphologically corresponded to lymphocytes (thick arrow; A-C). In the gastric cancer field D–F. negative or attenuated expression of 
NOVA1 was frequently observed in the overall microenvironment. Within the gastric cancer-embedded field, tumor cells (thin arrows; 
D-F), stromal spindle cells (dotted arrow; E-F), and immune cells of lymphoid structures (dotted area and thick arrows; D-F) frequently 
showed negative or attenuated expression of NOVA1. In another gastric cancer cases G. negative-to-attenuated NOVA1 expression was 
noted in immune cells (thick arrow), endothelial cells (thin arrow), fibroblasts or support cells (dotted arrow), and cancer cells (empty 
arrow). In the NOVA1-decreased cases (D-G), certain immune cells, stromal spindle cells, and epithelial cells of tumor glands occasionally 
showed positive NOVA1 expression, and such cells were admixed with many NOVA1-negative cells within the microenvironment (D-G; 
see the red-colored arrow in E). This feature may suggest the gradual attenuation of NOVA1 within the gastric cancer tissue field. In a 
gastric cancer case showing strong NOVA1 expression in the microenvironment H. most immune cells that expressed NOVA1 strongly 
(thick arrow; H) were identified as CD3-positive T lymphocytes (thick arrow); I. Most cells within the germinal centers, corresponding 
to the B cell zone, were negative for NOVA1 (dotted area; H). Tumor cells expressed NOVA1 strongly in this case (empty arrow; H). The 
microscopic figures were captured at x200 magnification power.
When comparing the proportions of NOVA1 expression between non-tumor gastric tissues and gastric cancer tissues, weak NOVA1 
expression in spindle cells (support cells, fibroblasts, endothelial cells) was more frequent, and strong NOVA1 expression was relatively 
less frequent in the gastric cancer field than in the non-tumor gastric tissue field
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for NOVA1. Although most mature small T cells were 
also negative for NOVA1, a small number of T cells did 
express this protein (Figures 6E–6L).
NOVA1 protein expression in T cell and B cell 
lymphoma tissues
Given that only small numbers of T lymphocytes in 
normal palatine tonsils expressed NOVA1 among immune 
cells while most lymphocytes involved in inflammation 
observed in the gastritis cases expressed high levels 
of NOVA1, we concluded that NOVA1 is increased in 
activated T cells.
To test this hypothesis, we evaluated NOVA1 
expression in peripheral (mature) T cell lymphoma tissues 
(n = 30), which are characterized by high levels of T cell 
activation. In most cases of T cell lymphoma, tumor T 
cells as well as stromal fibroblasts and endothelial cells 
Figure 5. The prognostic meaning of attenuated NOVA1 expression in gastric cancer tissues. Attenuated NOVA1 protein 
expression in spindle cells A. immune cells B. and tumor cells C. in gastric cancer fields was associated with inferior overall survival when 
compared to strong NOVA1 protein expression. The survival data was not available in one case, and analysis was performed using cases 
(n = 249) that had reliable information during the follow-up time. Survival function curves and survival rates were determined using the 
Kaplan-Meier method, and differences in survival rates were compared using the log-rank test.
Figure 4. (Continued) J. For immune cells K. and epithelial cells L. similar results were observed. Statistically significant differences 
are indicated by **, which signify P < 0.001 as determined using the Chi-square test. The expression patterns of NOVA1 among immune 
cells and stromal spindle cells M. immune cells and tumor cells N. and stromal spindle cells and tumor cells O. were closely correlated to 
each other. The correlation coefficient (r) with statistical significance (P value) was determined using the Spearman correlation test.
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also frequently showed strong NOVA1 expression (Figures 
7A–7B). To analyze NOVA1 expression in activated 
B cells, another type of immune cell, B cell lymphoma 
tissues (n = 30) were also investigated. All tumor B cells 
were negative for NOVA1 protein. Stromal spindle cells 
also frequently showed attenuated NOVA1 expression in 
most B cell lymphoma cases. Non-tumor immune cells 
involved in inflammation within the B cell lymphoma 
microenvironment were also frequently negative for 
NOVA1, although this observation was based on a small 
number of cases (Figures 7C–7D). Overall, 70% of tested 
T cell lymphomas (21 of 30) showed strong NOVA1 
expression while none of the tested B cell lymphomas 
revealed strong NOVA1 expression (Figure 7E).
Correlation of NOVA1 expression in immune 
cells with T cell density and regulatory T cell 
function
NOVA1 was increased mainly in activated T cells 
of non-tumor inflammation and T cell lymphomas. 
In immune cells of the gastric cancer field, however, 
NOVA1 expression was frequently decreased despite the 
histomorphologic features of inflammation formed in the 
gastric cancer field showing similarities with those of non-
tumor inflammation, as in gastritis. 
To determine whether decreased NOVA1 
expression of immune cells (T cells) in the gastric 
cancer microenvironment is correlated with T 
exhaustion or abnormal function of regulatory T cells 
(Tregs), the density of T cells and FOXP3-positive T 
cells were counted using the set of gastric cancer tissues 
(n = 250; Figures 8A–8I). The T cell density was not 
significantly different according to NOVA1 expression 
in the immune cells; T cell density was similar among 
cases showing weak, moderate, and strong NOVA1 
expression (Figure 8J). However, the cell number of 
Foxp3-positive T cells decreased more in cases showing 
weak NOVA1 expression than cases showing moderate 
or strong NOVA1 expression (Figures 8K) in the 
immune cells.
Figure 6. NOVA 1 expression in immune cells of lymphoid structures and stromal cells of the extracellular matrix. In 
normal palatine tonsils, NOVA1-expressing cells had large, ovoid to spindle-shaped nuclei. These cells were frequently found as single 
isolated cells throughout the cortical zones of lymphoid follicles, the paracortical zones, and extracellular matrix (nuclear expression in 
brown; A-L). Stromal spindle cells (fibroblasts and support cells, thin arrow; A) throughout the extracellular matrix consistently expressed 
NOVA1. Endothelial cells in the vasculatures (dotted arrow; A) were negative for NOVA1 in the non-inflamed tonsil stroma A. In areas 
where alpha smooth muscle actin-positive myofibroblasts or fibroblasts were proliferating (white dotted area, see details of cell morphology 
within the high magnification inset; B. H&E staining; C. alpha smooth muscle actin staining), strong NOVA1 expression was localized D. 
Double staining with NOVA1 (nuclear expression in brown) and CD20 (cytoplasm/membrane expression in red); E. and F. and double 
staining with NOVA1 and CD21 G. and H. revealed that almost all B cells and follicular dendritic cells were not NOVA1-positive. In the 
paracortical T zone, most T cells were not NOVA1-positive based on double staining with NOVA1 and CD3 I. and J. A small number of T 
cells, however, were positive for both NOVA1 and CD3 (thin arrow and inset; J). In this case, endothelial cells (dotted arrow; J) expressed 
NOVA1 variably with weak to moderate intensity. Almost all CD68-positive macrophages and dendritic cells were negative for NOVA1 K. 
and L. The microscopic figures were captured at x100 and x200 magnification power.
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NOVA1 protein expression in proximal resection 
margin tissues
Given that NOVA1 was strongly expressed in non-
tumor gastritis tissues while it was significantly attenuated 
in the gastric cancer field, we analyzed NOVA1 expression 
in histologically tumor cell-free proximal resection margin 
tissues. Among the set of 140 proximal resection margin 
samples, cases were randomly selected from those with 
high miR146b-5p expression and a poor prognosis 
(n = 34) as well as those with non-high miR-146b-5p 
expression and a favorable prognosis (n = 34). In the 
Figure 7. NOVA1 expression in T cell and B cell lymphomas. In T cell lymphomas A. and B. strong NOVA1 expression 
was observed in tumor cells (empty arrow), fibroblasts (dotted arrow in A), and endothelial cells (black arrow). Staining results for 
angioimmunoblastic T cell lymphoma (A) and anaplastic large cell lymphoma (B) are shown. In B cell lymphomas C. and D. tumor cells 
were negative for NOVA1 (empty arrow). Cases showing NOVA1-expressing fibroblasts and support cells are presented (dotted arrow) 
to compare expression patterns among cells. Note that small mature immune cells of reactive lymphoid structures within the diffuse large 
B cell lymphoma field were negative for NOVA1 (thick arrow, C). A diffuse large B cell lymphoma C. and mantle cell lymphoma (D) are 
shown. Among the tested T cell lymphomas (n = 30), 70% showed strong NOVA1 expression, while all of the tested B cell lymphomas (n 
= 30) revealed weak (negative) NOVA1 expression (Figure E). The microscopic figures were captured at x200 magnification power.
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Figure 8. T cell density and regulatory T cell function according to NOVA1 expression in gastric cancer tissues. In a case 
of weak NOVA1 expression in the immune cells A. many CD3-positive T cells are infiltrating into the gastric cancer field B. but FOXP3-
positive regulatory T cells are rarely noted C. In a case of moderate NOVA1 expression in the immune cells D. some of the infiltrating 
CD3-positive T cells are positive for FOXP3 E. and F. In a case of strong NOVA1 expression G. CD3-positive T cells are admixed with 
the poorly differentiated gastric cancer cells H. and FOXP3-positive regulatory T cells are frequently noted I. The microscopic figures 
were captured at x400 magnification power. T cell density was not different but similar among cases showing weak (the case number, n 
= 97), moderate (n = 121), and strong (n = 32) NOVA1 expression in immune cells (T cells) of the gastric cancer tissue field J. However, 
the cell density of FOXP3-positive regulatory T cells decreased more in cases showing weak NOVA1 expression in immune cells than in 
cases of moderate or strong NOVA1 expression K. Densities (cell number) of CD3-positive T cells and FOXP3-positive T cells within 
the tumor microenvironment were counted in the five most representative 400-magnification high-power fields and then averaged after 
immunohistochemical staining with CD3 and FOXP3 in the set of gastric cancer tissues (n = 250). Statistically significant differences are 
indicated by *, which signifies P < 0.05 as determined using the one-way ANOVA test.
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high-miR146b-5p and poor-prognosis group, the weak 
NOVA1 expression was relatively more frequent, and 
strong NOVA1 expression was relatively less frequent in 
immune cells of the microenvironment (Figures 9A–9E), 
although a statistically significant difference in NOVA1 
expression was not observed for stromal spindle cells and 
epithelial cells.
Inhibition of NOVA1 by miR-146b-5p in gastric 
cancer cells and fibroblasts
Endogenous NOVA1 expression level was higher 
in NHDF (fibroblast cell line) than in other tested cells: 
HUVEC (endothelial cell line) and SNU16 (gastric cancer 
cell line) cells expressed NOVA1 at low levels. NOVA1 
gene expression was not detected in SNU5 (gastric 
cancer cell line) or SUN620 (gastric cancer cell line) cells 
(Supplementary Figure S2).
After we increased or decreased miR-146b-5p 
expression through transfection with miR-146b-mimics 
and through co-transfection with both miR-146b mimics 
and miR-146b-5p inhibitors (Figure 10A), expression of 
the NOVA1 mRNA level was measured in SNU16 cells 
(gastric cancer cell line) and NHDF cells (fibroblast 
cell line) using the quantitative reverse transcription 
polymerase chain reaction (RT-PCR) method (Figure 
10B). At 72 hours after transfection, it was observed that 
expression of NOVA1 mRNA was reciprocally decreased 
or increased in SNU16 and NHDF cells in response to 
miR-146b-5p expression (Figures 10A–10B).
To analyze possible changes of NOVA1 in stromal 
cells through interaction with cancer cells according 
to miR-146b-5p expression, we used the co-culture 
system. After miR-146b mimics were transfected to 
increase miR-146b-5p expression and both miR-146b 
mimics and miR-146b-5p inhibitors were co-transfected 
to decrease miR-146b-5p expression in each SNU16 
(gastric cancer cell line) and NHDF (fibroblast cell line) 
cell, SNU16 and NHDF cells were co-cultured. At 72 
hours after transfection, NOVA1 mRNA expression of 
NHDF was measured using quantitative RT-PCR. NOVA1 
mRNA reciprocally decreased or increased in response 
to increased or decreased miR-146b-5p in NHDF cells 
themselves (Figure 10C; a, d–g). Even when NHDF cells 
were not transfected, the NOVA1 mRNA level reciprocally 
increased in response to transfected miR-146b-5p 
inhibitors of the co-cultured SNU16 cells (Figure 10C; a, 
c).
Cell survival, proliferation, and invasiveness did not 
change significantly during 72 hours of observation, nor did 
cell death (apoptosis or necrosis; Supplementary Figure S3).
DISCUSSION
We investigated the characteristics of occult 
residual disease in remnant tissues, as this is related to 
poor patient prognosis. We hypothesized that if tumor-
promoting changes remain in the remnant tissues, the 
remnant microenvironment may be the reservoir for 
tumor relapse. Considering that the microenvironment 
is an organized complex of epithelial cells, the structural 
matrix, fibroblasts, endothelial cells, and immune cells, 
we investigated the predominant molecular changes and 
associated cell types in the remnant microenvironment that 
were thought to be components of occult residual disease 
related to poor clinical outcomes. We selected proximal 
resection margin tissue sections of gastric cancers, as the 
proximal resection margin represents the nearest remnant 
microenvironment where occult residual disease is likely 
to be present. The microenvironment of the proximal 
resection margin area is located within the pathway where 
potential occult residual disease could spread into the 
nearest remnant tissues (Figure 1).
Several miRNAs (hsa-miR-223-3p, -142-5p, -146b-
5p, -150-5p, -363-5p, -532-5p, -502-3p, -1244, -132-
5p, -933, -638, and -3195) were aberrantly expressed in 
proximal resection margin tissues which contained tumor 
cells at the microscopic level from patients who underwent 
R1 resection and died of cancer recurrence. These markers 
were considered to be the predominant epigenetic markers 
of the remnant microenvironment containing low numbers 
of tumor cells that survived after being separated from the 
original mass and then progressed into clinically apparent 
tumor relapse.
Several studies have demonstrated that 
microRNAs are present in resident cells within the tumor 
microenvironment[21]; however, most miRNAs found 
in the present study have not previously been reported in 
earlier studies. Such previous studies used cell lines or a 
single cell type microdissected from the microenvironment 
in which the tumor mas was embedded. Differences in 
study models may therefore account for this discrepancy 
between studies.
The 12 miRNAs were validated in terms of their 
clinical implications using a set of advanced gastric 
cancer cases that had a tumor-free proximal resection 
margin (R0). Among these, increased miR-146b-5p 
was significantly correlated with cancer relapse and 
poor survival outcomes. Increased miR-146b-5p in the 
proximal resection margin tissues was correlated with 
intraperitoneal (locoregional) recurrence and distant 
metastasis even after completing curative treatment. In 
addition, increased miR-146b-5p was correlated with 
an inferior overall survival rate and determined to be an 
independent prognostic factor. These findings suggest that 
increased miR-146b-5p in the remnant microenvironment 
may be a strong predictor of tumor recurrence and poor 
patient outcome. Only a small number of studies on 
miR-146b-5p have been published. Recent reports have 
demonstrated the role of miR-146b-5p in cancer growth; 
miR-146b-5p is involved in the epithelial mesenchymal 
transition (EMT) through regulation of PRRX1 or ZNRF, 
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Figure 9. NOVA1 expression in the proximal resection margin tissues. In the case of the non-high miR146b-5p and favorable 
prognosis group, strong NOVA1 expression was noted in immune cells of the proximal resection margin tissue A. and B. In the case of the 
high-miR146b-5p and poor prognosis group, weak NOVA1 expression was observed in immune cells of the microenvironment C. and D. 
The lymphoid structures of these cases appeared to be histologically similar; however, the NOVA1 expression level in the immune cells 
differed between these cases (dotted area and black arrow; A-D). In case (D) certain immune cells occasionally showed positive NOVA1 
expression, and such cells were admixed with many NOVA1-negative cells within the microenvironment (see the red-colored arrow in 
D). This feature may suggest the gradual attenuation of NOVA1 within the microenvironment. The microscopic figures were captured at 
x200 magnification power. When comparing the proportions of NOVA1 expression in immune cells between the two groups (non-high 
miR146b-5p and favorable prognosis group versus high-miR146b-5p and poor prognosis group), weak NOVA1 expression was relatively 
more frequent, and strong NOVA1 expression was less frequent E. Statistically significant differences are indicated by *, which signifies P 
< 0.05 as determined using the Chi-square-test.
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which are EMT markers, [22,23] and it is also involved 
in nuclear factor kB (NF-kB) signaling via regulation of 
TRAF6 during cancer development and immune reaction 
[24].
The present study was not about miR-146b-5p 
function on cancer cells. We focused on the remnant 
tissues in which the microenvironment was histologically 
tumor cell-free yet the patient had a poor prognostic 
outcome. In the present study, the NOVA1 gene was 
identified as the target gene inhibited by miR-146b-5p 
in the tumor cell-free proximal resection margin tissues 
characterized by poor clinical outcomes. NOVA1 (neuro-
oncological ventral antigen 1) is known to be involved in 
the neuronal splicing program [25–28]; the role of NOVA1 
has been rarely investigated in other types of cells or 
cancers.
To find target cells correlated with NOVA1 
dysregulation, we performed a morphoproteomic analysis 
using immunohistochemistry. This method is one of the 
best tools for cytological and histological localization 
and identification of cells expressing translated target 
genes within the complex tissue microenvironment. The 
Figure 10. In vitro analysis of NOVA1 modulation by miR-146b-5p in gastric cancer cells, endothelial cells, and 
fibroblasts. miR-146b mimics were transfected to increase miR-146b-5p expression, and both miR-146b mimics and miR-146b-5p 
inhibitors were co-transfected to decrease miR-146b-5p expression in SNU16 (gastric cancer cell line) and NHDF (fibroblast cell line) 
cells. At 72 hours after transfection, we confirmed that the level of miR-146b-5p increased or decreased according to the transfection A. 
According to the miR-146b-5p expression level A. variation of NOVA1 mRNA expression was observed in NHDF and SNU16 cells B. The 
expression levels of miR-146b-5p and NOVA1 mRNA were evaluated using quantitative reverse transcription PCR. Relative expression 
levels (2-ddCt) of miR-146b-5p and NOVA1 mRNA were determined by comparing them with the respective levels of cells transfected with 
scrambled oligonucleotide in each cell line. The values shown in the histogram are means ± SD. Statistically significant differences are 
indicated by *, which signifies P < 0.05, and **, which signifies P < 0.001 as determined using two-sample t-tests (A and B). After the 
miR-146b mimics were transfected to increase miR-146b-5p expression (Up) and both miR-146b mimics and miR-146b-5p inhibitors 
were co-transfected to decrease miR-146b-5p expression (Down) in each SNU16 (gastric cancer cell line) and NHDF (fibroblast cell line) 
cell (upper lane), SNU16 and NHDF were co-cultured. At 72 hours after transfection, NOVA1 mRNA expression was measured using 
quantitative RT-PCR. The NOVA1 mRNA level of NHDF was analyzed and subsequently found to reciprocally decrease or increase in 
response to increased or decreased miR-146b-5p in NHDF cells themselves
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changes of NOVA1 expression were distinctively different 
in immune cells and in stromal spindle cells, such as 
fibroblasts, reticular support cells, and endothelial cells, 
according to the tissue conditions as follows: normal 
physiologic lymphoid tissues, non-tumor gastric tissues, 
gastric cancer tissues, immune T or B cell malignancy 
tissues, and tumor-free proximal resection margin tissues 
with or without increased miR-146b-5p expression. 
Among immune cells, NOVA1 expression was 
restricted to T lymphocytes. In the non-activated 
(inflamed), physiologic secondary lymphoid structures 
of the palatine tonsils, only small numbers of T cells 
expressed NOVA1. This NOVA1 expression increased 
in most T cells when involved in non-neoplastic 
inflammatory conditions, such as chronic gastritis or 
Helicobacter gastritis. Tumor T cells (T cell lymphomas) 
also demonstrated increased NOVA1 expression. In gastric 
cancer fields, however, NOVA1 protein expression was 
frequently decreased in immune cells (T cells) within 
the tumor microenvironment. In addition, decreased 
NOVA1 expression in immune cells in the gastric 
cancer field correlated with poor patient prognosis. 
The histomorphological features of inflammation (or 
tertiary lymphoid structures) [16–20] within the gastric 
cancer field were similar to those in non-tumor gastritis 
tissues. However, the immune surveillance provided by 
inflammation may have been dysregulated in the NOVA1-
decreased gastric cancer field.
We noted that decreased NOVA1 expression in T 
cells was not the result of the depletion or exhaustion of 
T cells. However, cell numbers of FOXP3-positive T cells 
were more decreased in gastric cancer cases showing weak 
NOVA1 expression in T cells. Transcription factor forkhead 
box P3 (FOXP3) is known to be the master regulator in 
regulatory T cells; therefore, it is also known to be the 
most specific marker for the identification of regulatory T 
cells (Tregs). Tregs are well known to play a central role in 
the immune response to tumors as well as various disease 
conditions. Lack or paucity of FOXP3-positive Tregs is 
known to lead to immunodysregulation. [29, 30]. The 
decreased NOVA1 expression in immune cells (T cells) 
seems to be correlated with suppressed Tregs in the gastric 
Figure 10. (Continued) C; a, d-g. The NOVA1 mRNA level increased in response to transfected miR-146b-5p inhibitors of the co-
cultured SNU16, even when NHDF cells were not transfected (C; a, c). The values shown in the histogram are means ± SD. Statistically 
significant differences are indicated by *, which signifies P < 0.05, and **, which signifies P < 0.005 as determined using the two-sample 
t-test. Relative expression levels (2-ddCt) of NOVA1 mRNA were evaluated using quantitative reverse transcription PCR by comparing them 
with the respective levels of cells transfected with scrambled oligonucleotide or non-transfected cells. No, no transfection; Up, transfection 
of hsa-miR-146b-5p mimics; Down, transfection of both hsa-miR-146b-5p mimics and inhibitors.
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cancer field. The suppressed Tregs may lead to immune 
dysfunction in the NOVA1-decreased gastric cancer field. 
A small number of recent studies show the presence of 
the FOXP3-miR-146a/b-NF-κB axis in breast cancer or 
prostate cancer, although such studies focus on cancer cells 
and direct binding between miR-146a and FOXP3.[31, 32] 
From these findings, however, it could be suggested that 
increased miR-146b-5p may be involved in the suppression 
of FOXP3-positive Tregs directly or indirectly through 
NOVA1 dysregulation or other signaling pathways.
Interestingly, T cell lymphomas, which are extreme 
examples of T cell activation, showed strong NOVA1 
expression in both tumor cells and stromal cells. B cells of 
normal tonsils (normal, physiologic secondary lymphoid 
structures) and B cell lymphomas did not express NOVA1. 
Stromal spindle cells mixed with B cell lymphomas also 
frequently showed attenuated NOVA1 expression. Given 
that the NOVA1 expression level was closely correlated 
between immune cells, stromal spindle cells, and tumor 
cells as shown in gastric cancer tissues, changes of 
NOVA1 expression may be shared among resident cells of 
the microenvironment. In tumors with increased NOVA1 
expression, such as T cell lymphomas, strong NOVA1 
expression may be induced in stromal spindle cells or 
vice versa. In tumors with attenuated or negative NOVA1 
expression such as B cell lymphomas, upstream signaling 
molecules such as miR-146b-5p may inhibit NOVA1 in 
overall resident cells within the microenvironment. In 
fact, several recent studies have revealed that changes of 
miRNAs in the tumor microenvironment likely occur by 
crosstalk among resident cells through various signaling 
methods such as autocrine and/or paracrine manners.[21].
In the present study, fibroblasts, stromal spindle 
cells, and/or reticular support cells of the extracellular 
matrix within the microenvironment constitutively 
express NOVA1 in normal or non-neoplastic inflammatory 
conditions. In fact, a recent study showed that NOVA1 was 
enriched in normal fibroblasts independent of tissue or 
organ origin and suggested that NOVA1 may be involved 
in the splicing programs of normal fibroblasts. [33] The 
present study noted that NOVA1 expression was frequently 
decreased in stromal fibroblasts and spindle cells in 
the gastric cancer field. In addition, decreased NOVA1 
expression in stromal fibroblasts and spindle cells of the 
gastric cancer field was related to poor patient prognosis.
Stromal spindle cells are major components of 
tissue inflammation or tertiary lymphoid structures 
within the microenvironment. [16–18] Recent studies 
showed that stromal spindle cells and fibroblasts actively 
regulate immune cells in the inflammatory process and 
are involved in immune escape of cancers.[16, 34, 35] In 
addition, fibroblasts and stromal spindle cells, or cancer-
associated fibroblasts (CAFs), are major components of 
the tissue matrix.[21, 35, 36] The extracellular matrix 
has been shown to be involved in tumor cell growth, 
angiogenesis, invasion, and immune escape.[34, 35] 
Decreased NOVA1 function in stromal spindle cells may 
also be involved in the escape of aggressive cancers from 
immune surveillance. miR-146b-5p may be a regulator of 
fibroblasts through inhibiting NOVA1 expression. If fact, 
CAFs are known to be epigenetically regulated through 
miRNAs.[21, 37] Considering that NOVA1 is an alternative 
splicing factor, deregulated splicing programs inhibited by 
miR-146b-5p in fibroblasts and the stromal matrix may be 
associated with tumor progression in remnant tissues.
Given that the findings of NOVA1 expression 
was closely correlated among resident cells of the 
microenvironment, we attempted to demonstrate the 
possible interaction among stromal cells and cancer 
cells in the process of NOVA1 expression as a response 
to miR-146b-5p. In the study, the NOVA1 mRNA level 
was increased in fibroblast cell lines in response to 
miR-146b-5p inhibitors, which were transfected to the 
co-cultured gastric cancer cells even when fibroblast 
cells themselves were not transfected by miR-146b-
5p inhibitors. Although we didn’t observe changes of 
NOVA1 by possible crosstalk of miR-146b-mimics, it was 
suggested that crosstalk of molecules may occur between 
cells within the microenvironment. Our hypothesis could 
be also supported by several recent studies on the crosstalk 
of miRNA signals among resident cells [21]. 
As for the sources of increased miR-146b-5p in 
the tumor cell-free remnant tissues, secondary spreading 
through the stromal matrix or vasculatures from the 
original tumor site may be possible, as the expression of 
miR-146b-5p increased as the distance from the original 
tumor decreased. However, even in relatively distant areas 
from the original tumor site, increased miR-146b-5p was 
also frequently observed. Recent evidence indicates that 
primary changes could also occur in mesenchymal stroma, 
and alteration of resident cells in the microenvironment 
could initiate cancers. [38] Increased miR-146b-5p could be 
the primary change in resident cells within remnant tissues.
We made several new important findings, although 
several of these require additional confirmation in future 
studies. Particularly, our findings of decreased NOVA1 in 
the immune cells, stromal spindle cells, and cancer cells 
were more specific to gastric cancer tissues than to non-
tumor gastric tissues. In addition, decreased NOVA1 in 
the gastric cancer field was associated with poor patient 
prognosis. Therefore, the NOVA1 expression pattern 
could be a candidate biomarker that could be easily 
tested during routine diagnosis using human samples 
and immunohistochemistry. The usefulness of NOVA1 
immunostaining could be extended to various cancer types 
after further validation studies. 
In summary, occult residual disease can remain 
in histologically tumor cell-free remnant tissues after 
removal of cancers, and this occult residual disease is a 
strong risk factor for tumor relapse. Specifically, increased 
miR-146b-5p in the proximal resection margin tissues, 
representing the nearest remnant tissues after gastrectomy, 
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was significantly associated with tumor relapse and 
poor outcomes in gastric cancer patients. miR-146b-5p 
inhibited expression of NOVA1, an alternative splicing 
factor, in immune cells and stromal spindle cells within 
the remnant microenvironment. Immune cells and stromal 
spindle cells with abnormal NOVA1 expression could be 
the main component of occult residual disease in remnant 
tissues after tumor removal and are therefore potential 
causes of tumor relapse.
METHODS
Selection of candidate microRNAs
Candidate microRNAs that showed aberrant 
expression in the remnant microenvironment and were 
possibly related to aggressive oncologic outcomes were 
identified using clinical samples of the proximal resection 
margin tissues and microarray analysis. Positive control 
samples (n = 4) were obtained from R1 resection cases 
(microscopically tumor-present in the resection margin) 
[9, 15] with poor oncologic outcomes (died of cancer 
recurrence), and the volume of tumor cells was found to 
be less than 10% of the entire tested area. We reasoned 
that these controls were appropriate for investigating 
the potential molecular changes within the surrounding 
microenvironment, in which low numbers of tumor 
cells may have survived, interacting with resident cells 
of the remnant microenvironment. Negative control 
samples (n = 4) were obtained from cases of R0 resection 
(microscopically tumor-free resection margin) [9, 15] 
with a favorable clinical outcome (survived without any 
event during a follow-up time of more than 5 years). 
Detailed clinicopathological information on the control 
cases is provided in the supplementary information and 
Supplementary Table S1.
Total RNA for microarray experiments was 
extracted (GENOCHECK Ltd., Seoul, Korea) using two 
slices of formalin-fixed paraffin-embedded (FFPE) tissue 
sections dissected at a thickness of 10-mm. The quality 
and quantity of RNA were checked using an Agilent 
Bioanalyzer (Agilent Technologies, CA, USA) and 
determined to be appropriate for microarray expression 
analysis. Microarray analysis was performed using 
Agilent Human miRNA arrays (8x60K v16.0, Agilent 
Technologies), which contained probes specific for 1205 
human and 144 human viral miRNAs. Candidate miRNAs 
were selected when the expression level of an individual 
miRNA differed significantly (P-value < 0.05) between 
the positive and negative controls and the fold change 
was >1.5 based on comparison of the mean values of the 
positive and negative controls (Supplementary Data Set 1).
Clinical validation of selected candidate miRNAs
The expression pattern of selected candidate miRNAs 
in the microenvironment was analyzed in the set of proximal 
margin tissues obtained from 140 advanced gastric cancer 
cases. These cases had undergone radical surgery and 
curative R0 resection (tumor-negative in the proximal and 
distal resection margin lines).[9, 15] Standard gastrectomy, 
which included resection of at least two-thirds of the 
stomach and D2 lymph node dissection, was performed by 
gastric surgery specialists at Gangnam Severance Hospital 
between 2005 and 2008. No preoperative treatment was 
performed. The histopathology for each case was reviewed 
by pathologists. The median follow-up period was 67.4 
months (range, 0.7 to 101.8 months). Clinicopathological 
details are described in the supplementary information 
and Supplementary Table S5. For negative controls, we 
used proximal resection margin tissue samples from 10 
cancer-free individuals who had undergone gastrectomy at 
Gangnam Severance Hospital between 2005 and 2008 due 
to an ulcer or other benign inflammatory lesion.
FFPE tissues submitted as the proximal margin 
section were prepared under the conventional surgical 
and pathologic examination protocols (Figure 1).[8, 14, 
15] The tested area was histologically confirmed to be 
tumor-free on microscopic observation. RNA, including 
microRNA, was isolated using the miRNeasy FFPE Kit 
(Qiagen, Hilden, Germany). cDNAs were synthesized 
using looped reverse transcription primers specific to each 
miRNA species. Looped reverse transcription and forward 
and reverse primers for each microRNA (hsa-miR-223-
3p, -142-5p, -146b-5p, -150-5p, -363-5p, -532-5p, -502-
3p, -1244, and -132-5p, as well as a housekeeping gene, 
U6sn) are listed in Supplementary Table S6. Expression 
of miRNA species was assayed quantitatively. In brief, 
a 20 μl mixture containing 2 μl of cDNA, 2 U of i-Taq 
DNA polymerase (iNtRON, Seongnam, Korea), 2 μl of 
10X i-Taq reaction buffer (iNtRON), 2 μl of 2.0 mM 
dNTP mixture (Takara, Japan), 1 μl of 5 pmol/μl forward 
primer, 1 μl of 5 pmol/μl reverse primer, 0.9 μl of 5X 
SYBR Green (ROCHE, Switzerland), and 10.9 μl of 
tertiary distilled water was prepared, and amplification 
was performed using a StepOnePlus Real-Time PCR 
instrument (Applied Biosystems, CA, USA) under the 
following conditions: denaturation at 94°C for 5 min 
followed by 30 cycles of 94°C for 15 sec and 66°C for 40 
sec (fluorescence signal acquisition was performed during 
this phase). Immediately after amplification, melting curve 
analysis was performed. All samples were analyzed twice 
to confirm reproducibility. Using StepOnePlus Real-Time 
PCR System software (version 2.1; Applied Biosystems), 
the expression value (2-ddCCT) of each case was normalized 
to the median expression value of negative controls. High 
expression was defined when the normalized value was >2 
(fold-change > 2).
Finding target genes of the miRNA
For the validated miRNA that had significant 
clinical implications, predicted target messenger RNAs 
were queried in a web-based database ( http://mirecords.
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umn.edu/miRecords; http://www.microrna.org/microrna), 
and 27 highly relevant genes and three reference genes 
were selected to form a custom-based array set. FFPE 
tissues of the proximal resection margin section were 
selected from the above set of proximal resection margin 
tissues (n = 140). To create a positive control group, 
24 cases with abnormal expression of the identified 
miRNA in the proximal resection margin tissues and a 
poor clinical outcome were selected randomly. For the 
negative controls, 24 stage-matched cases with no aberrant 
expression of the miRNA and a favorable prognosis were 
selected. After quality assessment of the extracted RNA, 
12 cases from the positive control group and 23 cases 
from the negative control group were ultimately analyzed. 
Clinicopathological information on these control samples 
is summarized in Supplementary Table 7. Expression 
analysis was performed using nCounter Gene Expression 
Custom CodeSet (30 Genes × 48 Reactions; NanoString 
Technologies, Seattle, WA, USA). Predicted target gene 
expression is summarized in Supplementary Data Set 2.
Clinical samples for cellular localization of 
translated target genes
We investigated the expression of the target protein 
of the candidate miRNA in each cell type making up 
the microenvironment, using FFPE tissues from clinical 
samples.
Normal palatine tonsil tissues (n = 10), a set of non-
tumor gastric tissues (n = 45), and a set of advanced gastric 
cancer tissues (n = 250) were included in the analysis. 
Tonsil tissues were obtained via tonsillectomy from cancer-
free individuals. A set of normal gastric tissue (n = 45) 
was used as a control, representing a non-tumor gastric 
microenvironment. A set of gastric cancer tissues (n = 250) 
was used to analyze the tumor-embedded microenvironment. 
These gastric cancer tissues were obtained from surgical 
resection performed at Korea University Guro Hospital from 
2002 to 2005. Details regarding this set of gastric cancer 
tissues are summarized in the supplementary information 
and Supplementary Table 8.
For comparative analysis, mature (peripheral) 
T cell lymphoma tissues (n = 30) and mature B cell 
lymphoma tissues (n = 30) were included as examples of 
activated immune cells. The subtypes were as follows: 
peripheral T cell lymphoma (not otherwise specified, 
n = 15), angioimmunoblastic T cell lymphoma (n = 5), 
anaplastic large cell lymphoma (n = 10), diffuse large 
B cell lymphoma (n = 20), follicular lymphoma (n = 5), 
mantle cell lymphoma (n = 2), and marginal-zone B cell 
lymphoma (n = 3). All lymphoma tissue samples were 
reviewed by hematopathologists (SOY and WIY) based 
on current World Health Organization (WHO) criteria.[39] 
Representative tissue sections of palatine tonsils and 
tissue microarrays for non-tumor gastric tissue, gastric 
cancer tissues, and lymphoma tissues were prepared.
Immunohistochemistry
Immunohistochemistry was performed using a 
Ventana Bench Mark XT Autostainer (Ventana Medical 
Systems, Tucson, AZ, USA) and a LEICA BOND-III 
Autostainer (Leica Biosystems, Newcastle Upon Tyne, 
UK). Tested primary antibodies were as follows: NOVA1 
(dilution 1:500; Abcam, Cambridge, UK), CD68 (dilution 
1:150; DAKO), CD20 (dilution 1:1600; clone L26; DAKO), 
CD3 (dilution 1:200; LabVision, Fremont, CA, USA),
CD4 (dilution 1:200; Cell Marque, Rocklin, CA, 
USA), FOXP3 (dilution 1:100; Aviva Systems Biology, 
CA, USA), myeloperoxidase (dilution 1: 2000, DAKO), 
CD34 (dilution 1:50; clone QBEnd 10; DAKO), S100 
(dilution 1:2000; DAKO), and alpha smooth muscle actin 
(dilution 1:500; clone 1A4; DAKO). Double staining 
with NOVA1/CD20, NOVA1/CD3, NOVA1/CD21, 
and NOVA1/CD68 was performed using palatine tonsil 
tissues for cellular localization of NOVA1 expression. 
Cell typing of immune cells and stromal spindle cells 
was also confirmed histomorphologically with H&E and 
immunohistochemical stains as follows: macrophages/
monocytes/dendritic cells (CD68, S100, myeloperoxidase), 
B-lymphocytes (CD20), T-lymphocytes (CD3), regulatory 
T cells (FOXP3), neutrophils (myeloperoxidase), stromal 
spindle cells (Schwann cells, fibroblasts, support cells, and 
endothelial cells; S100, smooth muscle actin, and CD34).
Grading of NOVA1 protein expression
Pathologists, including the hematopathologist, 
evaluated the cellular localization of NOVA1 expression 
for each cell type within the microenvironment under 
microscopic examination. NOVA1 expression scoring was 
semiquantitatively determined by staining intensity grade 
(1, no staining to weak intensity; 2, moderate intensity; 
3, strong intensity) multiplied by the percentage grade of 
positive cell nuclei (1, 0%–9%; 2, 10%–19%; 3, 20%–
29%; 4,30%–39%; 5, 40%–49%; 6, 50%–59%; 7, 60%–
69%; 8, 70%–79%; 9, 80%–89%; 10, 90%–100%) after 
modifying the previously-used semiquantitative approach.
[40] The resulting NOVA1 protein expression scores 
ranged from 1 to 30 and were classified as having strong 
(21-30), moderate (11-20), or weak (1-10) expression.
Density of T cells and FOXP3 expression
Cell densities (number) of T cells and FOXP3-
positive T cells were investigated according to NOVA1 
expression in T cells. Using the set of gastric cancer 
tissues (n = 250), the densities of CD3-positive T cells 
and FOXP3+ T cells that had infiltrated the tumor 
microenvironment were counted as follows according 
to the method of our previous study:[41] the five most 
representative 400-magnification high-power fields were 
selected. Preserved intact nuclei were counted manually, 
and the counted cell numbers were averaged.
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Cell lines and reagents
Gastric cancer cell lines SNU-5 (00005; KCLB, 
Seoul, South Korea), SNU-16 (00016; KCLB) and SNU-
620 (00620; KCLB) were purchased and maintained 
in RPMI1640 medium (22400-089, Gibco; Life 
Technologies, CA, USA) supplemented with 10% FBS 
(6000-044, Gibco; Life Technologies). Human umbilical 
vein endothelial cells (HUVEC; CC-2517; Lonza, Basel, 
Switzerland) were purchased and maintained in EGM 
(CC-3124; Lonza), and human dermal fibroblasts (NHDF; 
CC-2511;Lonza) were purchased and maintained in 
FGM-2 (CC-3132; Lonza).
Transfection
Scrambled control miRs (scrambled 
oligonucleotides for miR-146b-5p and miR-146b-5p 
inhibitors; AccuTarget™ miRNA mimic Negative control; 
Bioneer, Daejeon, South Korea), a hsa-miR-146b-5p 
mimic (Bioneer), and a hsa-miR-146b-5p inhibitor 
(Bioneer) were obtained and transfected at a concentration 
of 30 nM using lipofectamine reagent (L3000008, 
Invitrogen; Life Technologies). After 72 hours, cells were 
harvested. Experiments were performed independently 
three or more times. An Annexin V/propidium iodide 
(PI) assay (FITC Annexin V Apoptosis Detection Kit; BD 
Pharmingen, CA, USA) was performed to determine cell 
apoptosis or necrosis after transfection.
Co-culture of cell lines
SNU16 cells were co-cultured with NHDF cells on 
6-well plate polycarbonate membrane transwell inserts 
(Costa3412; Corning, MA, USA). After transfection of 
scrambled control miRs, the hsa-miR-146b mimic, and 
both the hsa-miR-146b mimic and the hsa- miR-146b-5p 
inhibitor, cells were co-cultured. After 72 hours, cells were 
harvested. Experiments were performed independently 
three or more times.
RNA isolation and quantification PCR
miRNA was isolated using a mirVana miRNA 
isolation kit (AM1560, Ambion; Life Technologies), and 
cDNA was constructed using the TaqMan MicroRNA 
Reverse Transcription kit (4366596, AB; Life Technologies) 
for miR146b-5p and U6. TaqMan probes used were as 
follows: has-mir-146b (001097, AB; Life Technologies) and 
U6 snRNA (001973, AB; Life Technologies). The average 
relative expression of miR146b-5p was determined by the 
comparative method (2-ddCt). After RNA isolation using the 
RNeasy Plus mini kit (74134; Qiagen, Hilden, Germany), 
cDNA was constructed using a cDNA synthesis kit (11754-
050, Invitrogen). TaqMan probes used were as follows: 
GAPDH (Hs99999905-m1, AB; Life Technologies) 
and NOVA1 (Hs00359592-m1, AB; Life Technologies). 
Quantitative PCR was performed using an ABI 
StepOnePlus™ (Applied Biosystems) with the following 
cycling parameters: 50°C for 2 min, 95°C for 5 min, and 
40 cycles of 95°C for 15 sec and 60°C for 1 min. Relative 
mRNA expression levels of NOVA1 were determined by the 
comparative method (2-ddCt).
Statistics
The Mann-Whitney (MW) U test, one-way ANOVA, 
two-sample t-test, x2 test, and Pearson’s or Spearman’s 
correlation test were used to analyze the significance of 
differences among the variables examined. Overall survival 
times were measured from the date of surgery to the date 
of death or last follow-up visit. Recurrence-free survival 
was defined as the time from surgery to the first clinical, 
radiological, and/or histological evidence of recurrence 
in intraperitoneal or distant organs. Patient survival rates 
were determined using the Kaplan-Meier method, and 
differences in survival rates were compared using the 
log-rank test. Multivariate analysis was performed using 
the Cox proportional hazards model. A two-sided P-value 
<0.05 was considered statistically significant. Statistical 
analyses were performed using IBM SPSS 22 software for 
Windows (IBM Corp, Somers, New York).
Study approval
The Institutional Review Board of Gangnam 
Severance Hospital, Yonsei University College of 
Medicine approved this study.
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